Prescriber Criteria Form

Stelara 2025 PA Fax 560-A v2 010125.docx Stelara (ustekinumab) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Stelara (ustekinumab).

Drug Name:

Patient Name:

Stelara (ustekinumab)

[No further questions.]

[If yes, then no further questions.]

Does the patient have a diagnosis of active psoriatic arthritis?

5

Patie	nt ID:				
Patient DOB:		Patient Phone:	Patient Phone:		
Presc	riber Name:	-			
Presc	riber Address:				
City: Prescriber Phone: Diagnosis:		State:	State: Zip:		
		Prescriber Fax:	·		
		ICD Code(s):	ICD Code(s):		
Plea	se circle the appropriate answer f	or each question.			
1	Has the patient previously receive A) plaque psoriasis, B) psoriatic [If yes, then no further questions	arthritis, C) Crohn's disease,		Yes	No
2	Does the patient have a diagnos [If no, then skip to question 5.]	is of moderate to severe plaq	of moderate to severe plaque psoriasis?		No
3	Does the patient meet any of the following criteria: A) at least 3 percent of the body surface area (BSA) was affected by plaque psoriasis at the time of diagnosis, B) crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) were affected by plaque psoriasis at the time of diagnosis? [If no, then no further questions.]		Yes	No	
4	Does the patient meet any of the following criteria: A) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., ultraviolet B [UVB], psoralen plus ultraviolet A [PUVA]) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, B) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, C) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e. at least 10 percent of the body surface area [BSA] or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected)?		Yes	No	

Yes

No

Prescri	ber (or Authorized) Signature: Date:		
, ,	ng this form, I attest that the information provided is accurate and true as of this date and the ntation supporting this information is available for review if requested by the health plan.	at the	
Comme	nts:		
	Does the patient have a diagnosis of moderately to severely active ulcerative colitis?	Yes	No
6	Does the patient have a diagnosis of moderately to severely active Crohn's disease? [If yes, then no further questions.]	Yes	No